Experimental combo shows promise for Tough-to-Treat melanoma
NCT ID NCT01659151
First seen Nov 06, 2025 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This phase 2 trial tested a combination of the targeted drug vemurafenib, special immune cells grown from the patient's own tumor (TIL), and high-dose IL-2 in 17 people with advanced melanoma that had spread. The goal was to see if this approach could shrink tumors and improve survival. The study is complete, and results help guide future research on immune-based treatments for melanoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vemurafenib (Zelboraf) plus tumor-infiltrating lymphocytes (TIL) and high-dose interleukin-2 (IL-2)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced melanoma that has spread.
What could go wrong
This was a very small, early-phase trial with only 17 people, so results may not apply to everyone. The treatment involves strong chemotherapy and high-dose IL-2, which can cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.